BioRestorative Therapies, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRTX research report →
Companywww.biorestorative.com
BioRestorative Therapies, Inc. , a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.
- CEO
- Lance Alstodt
- IPO
- 2012
- Employees
- 11
- HQ
- Melville, NY, US
Price Chart
Valuation
- Market Cap
- $1.53M
- P/E
- -0.14
- P/S
- 4.27
- P/B
- 0.50
- EV/EBITDA
- 0.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.09%
- Op Margin
- -3975.00%
- Net Margin
- -3089.55%
- ROE
- -423.84%
- ROIC
- -470.16%
Growth & Income
- Revenue
- $359.70K · -10.30%
- Net Income
- $-14,241,975 · -58.61%
- EPS
- $-1.58 · -36.21%
- Op Income
- $-15,647,132
- FCF YoY
- -30.81%
Performance & Tape
- 52W High
- $2.04
- 52W Low
- $0.16
- 50D MA
- $0.25
- 200D MA
- $0.97
- Beta
- 0.20
- Avg Volume
- 8.59M
Get TickerSpark's AI analysis on BRTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 6, 25 | Silva Francisco | other | 11,719 |
| Oct 6, 25 | Silva Francisco | other | 11,719 |
| Oct 6, 25 | ALSTODT LANCE | other | 15,625 |
| Oct 6, 25 | ALSTODT LANCE | other | 11,719 |
| Feb 14, 25 | Rosa David A | other | 52,632 |
| Feb 14, 25 | Williams Patrick F. | other | 52,632 |
| Feb 14, 25 | Kukekov Nickolay V. | other | 52,632 |
| Feb 14, 25 | Kristal Robert Eugene | other | 166,492 |
| Feb 14, 25 | Silva Francisco | other | 768,979 |
| Feb 14, 25 | ALSTODT LANCE | other | 791,885 |
Our BRTX Coverage
We haven't published any research on BRTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BRTX Report →